We Need to Talk About CRISPR
By Staff,
The Medicine Maker
| 03. 21. 2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later becoming a TV show writer (for hit shows such as ER, Law and Order, and Under the Dome), Baer realized that the promise of advanced medicine could quickly become a peril, if placed in the wrong hands. This inspired him to compile a collection of essays that asks how far could – or should – humanity develop it. The Promise and the Peril of CRISPR chronicles the human condition in the 21st century, and asks what is more valuable: saving lives, or wielding power? Here he discusses the duality of CRISPR.
What inspired you to compile a collection of essays about CRISPR specifically?
There are lots of reasons. It’s important to know who has access to the data, and the DNA. Is it safe? What are the unforeseen consequences? Will there still be problems once one piece of DNA...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...